ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1038

Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Abstract Number: 1039

CAR-T Therapy in Rheumatoid Arthritis: A Health Systems Analysis of Cost and Global Equity
Abstract Number: 1040

Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis
Abstract Number: 1041

Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model
Abstract Number: 1042

Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Abstract Number: 1043

The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
Abstract Number: 1044

Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Abstract Number: 1045

Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
Abstract Number: 1046

Cannabis Knowledge, Attitudes, and Practices Among Rheumatology Providers: Implications for Clinical Care and Education
Abstract Number: 1047

Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Abstract Number: 1048

Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Abstract Number: 1049

Provider Characteristics and Beliefs and Patient Factors Associated with Long-term Glucocorticoid Use in Patients with Rheumatoid Arthritis
Abstract Number: 1050

Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Abstract Number: 1051

Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
Abstract Number: 1052

“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].